Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

290 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study.
Banning AP, Serruys P, De Maria GL, Ryan N, Walsh S, Gonzalo N, Jan van Geuns R, Onuma Y, Sabate M, Davies J, Lesiak M, Moreno R, Cruz-Gonzalez I, Hoole SP, Piek JJ, Appleby C, Fath-Ordoubadi F, Zaman A, Van Mieghem NM, Uren N, Zueco J, Buszman P, Iniguez A, Goicolea J, Hildick-Smith D, Ochala A, Dudek D, de Vries T, Taggart D, Farooq V, Spitzer E, Tijssen J, Escaned J. Banning AP, et al. Among authors: gonzalo n. Eur Heart J. 2022 Mar 31;43(13):1307-1316. doi: 10.1093/eurheartj/ehab703. Eur Heart J. 2022. PMID: 34617993 Free PMC article. Clinical Trial.
Diagnosis and treatment of coronary vulnerable plaques.
García-García HM, Gonzalo N, Granada JF, Regar E, Serruys PW. García-García HM, et al. Among authors: gonzalo n. Expert Rev Cardiovasc Ther. 2008 Feb;6(2):209-22. doi: 10.1586/14779072.6.2.209. Expert Rev Cardiovasc Ther. 2008. PMID: 18248275 Review.
Impact of drug-eluting stent selection on long-term clinical outcomes in patients treated for unprotected left main coronary artery disease: the sirolimus vs paclitaxel drug-eluting stent for left main registry (SP-DELFT).
Meliga E, Garcia-Garcia HM, Valgimigli M, Chieffo A, Biondi-Zoccai G, Maree AO, Gonzalo N, Cook S, Marra S, Moretti C, De Servi S, Palacios IF, Windecker S, van Domburg R, Colombo A, Sheiban I, Serruys PW. Meliga E, et al. Among authors: gonzalo n. Int J Cardiol. 2009 Sep 11;137(1):16-21. doi: 10.1016/j.ijcard.2008.06.006. Epub 2008 Aug 6. Int J Cardiol. 2009. PMID: 18687481
Diabetic patients treated for unprotected left main coronary artery disease with drug eluting stents: a 3-year clinical outcome study. The diabetes and drug eluting stent for LeFT main registry (D-DELFT).
Meliga E, Garcia-Garcia HM, Valgimigli M, Chieffo A, Biondi-Zoccai G, Maree AO, Gonzalo N, Cook S, Cruz-Gonzalez I, Marra S, De Servi S, Palacios IF, Windecker S, van Domburg R, Colombo A, Sheiban I, Serruys PW. Meliga E, et al. Among authors: gonzalo n. EuroIntervention. 2008 May;4(1):77-83. doi: 10.4244/eijv4i1a14. EuroIntervention. 2008. PMID: 19112783
Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial.
García-García HM, Gonzalo N, Pawar R, Kukreja N, Dudek D, Thuesen L, Ormiston JA, Regar E, Serruys PW. García-García HM, et al. Among authors: gonzalo n. EuroIntervention. 2009 Jan;4(4):443-8. doi: 10.4244/eijv4i4a77. EuroIntervention. 2009. PMID: 19284065 Clinical Trial.
290 results